Trial Profile
Afatinib with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutation:phaseI study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 06 Jun 2019 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2016 Status changed from not yet recruiting to recruiting.